Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2006 Nov;60(11):1364-70.
doi: 10.1111/j.1742-1241.2006.01176.x.

Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study

V Barrios  1 , C Escobar, A Navarro, L Barrios, J Navarro-Cid, A Calderón; LAURA Investigators
Affiliations
Multicenter Study

Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study

V Barrios et al. Int J Clin Pract. 2006 Nov.

Erratum in

  • Int J Clin Pract. 2007 Apr;61(4):712

Abstract

To determine whether the antihypertensive effectiveness of lercanidipine was independent of the different cardiovascular risk levels. Patients with treated or untreated mild-to-moderate essential hypertension were included in a multicentre, prospective, non-comparative, open-label study. Patients received lercanidipine (10 mg/day, uptitrated to 20 mg/day) during 6 months. A total of 3175 patients, age 63 +/- 10 years, 51% women, were included. The cardiovascular risk was low in 237 patients, medium in 1396, high in 722, and very high in 820. At baseline, blood pressure (BP) was 159.5 +/- 11.7/95.2 +/- 7.4 mmHg. BP was progressively higher according to increase in cardiovascular risk. After 6 months of treatment, BP was 136.0 +/- 9.7/79.7 +/- 6.8 mmHg. The decrease in systolic BP and diastolic BP at each follow-up visit compared with baseline was statistically significant both in the intergroup and intragroup comparisons (p < 0.001). Mean decreases of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were -18.5/-13.8 mmHg in the low risk group, -23/-15.2 mmHg in the medium risk group, -24.4/-16.1 mmHg in the high risk group, and -27.4/-17.4 mmHg in the very high risk group. Most frequent side effects were oedema (5.1%), headache (3.3%), flushes (2.5%), and asthenia (1%). Only 1.7% of patients discontinued antihypertensive medication because of adverse events. Tolerability of lercanidipine was independent of the cardiovascular risk group. Lercanidipine was effective and well-tolerated in patients with mild-to-moderate hypertension in the daily practice. The effectiveness and safety of the drug were independent of the degree of cardiovascular risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean ± 1 SD decreases in systolic blood pressure (SBP) in the four risk groups for cardiovascular disease during the study period when compared with baseline
Figure 2
Figure 2
Mean ± 1 SD decreases in diastolic blood pressure (DBP) in the four risk groups for cardiovascular disease during the study period when compared with baseline
See this image and copyright information in PMC

References

    1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat. Q. 1988;41:155–78. - PubMed
    1. Thom TJ. International mortality from heart disease: rates and trends. Int. J. Epidemiol. 1989;18(Suppl. 1):S20–8. - PubMed
    1. Stewart AW, Kuulasmaa K, Beaglehale R, for the WHO MONICA Project Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. The World Health Organization MONICA Project. Int J Epidemiol. 1994;23:505–16. - PubMed
    1. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid. J Hum Hypertens. 1997;11:213–20. - PubMed
    1. Black HR. The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure. Am J Hypertens. 2003;16(Suppl. 1):4S–6S. - PubMed

Publication types